OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
44
Results
Show all
Save search
Copy query
Show results for
Unknown
(43)
Proteomics
(1)
Repository
MassIVE
(1)
Instrument Platform
LTQ Orbitrap
(1)
Publication Date
2017
(1)
Release Date
2025
(6)
2023
(6)
2021
(6)
2010
(4)
2024
(3)
2022
(3)
2017
(3)
2016
(3)
2011
(2)
2009
(2)
2026
(1)
2020
(1)
2018
(1)
2015
(1)
2013
(1)
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Not available
S-EPMC8462523
|
biostudies-literature
Cite
BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.
Not available
S-EPMC3091323
|
biostudies-literature
Cite
Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness.
Not available
S-EPMC10962734
|
biostudies-literature
Cite
Knockdown of Crispld2 in zebrafish identifies a novel network for nonsyndromic cleft lip with or without cleft palate candidate genes.
Not available
S-EPMC6138754
|
biostudies-literature
Cite
Evaluation of the effect of human immunodeficiency virus-related structural interventions: the connect to protect project.
Not available
S-EPMC4346420
|
biostudies-literature
Cite
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.
Not available
S-EPMC12280981
|
biostudies-literature
Cite
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.
Not available
S-EPMC10950785
|
biostudies-literature
Cite
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness.
Not available
S-EPMC12823409
|
biostudies-literature
Cite
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Not available
S-EPMC9412011
|
biostudies-literature
Cite
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Not available
S-EPMC7768340
|
biostudies-literature
Cite
Previous
page
1 / 5
You're on page
1
page
2
page
3
page
4
page
5
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets